I
t's the question that every grade school kid has to answer at some point or another-"What do you want to be when you grow up?" My mom still has the second grade paper on which I first wrote down that I wanted to be a "physician scientist." I'm quite certain that I probably didn't know exactly what a physician scientist was at the time. I certainly didn't know any physician scientists personally, nor was I exposed to academic environments in the tiny Minnesota town in which I grew up. All I'm certain of, was at that time, I liked reading about science. Unfortunately, I soon came to know the medical profession all too personally.
It was at 8 years of age that I first experienced bouts of severe arthritis and difficulty walking, followed by relentless high-grade fevers, headaches and weight loss. This was the beginning of months of being hospitalized and being poked, prodded, and having literally hundreds of IV sticks for laboratory draws, fluids, and antibiotics.
It was during this hospitalization as a kid, that I experienced what the difference was between compassionate medical care, and not so compassionate care. Often by myself in this cold sterile environment, lying as still as I could on a flat wooden bed (…it was thought that sitting up or moving around caused the infection to spread), I quickly learned which nurses and doctors I could trust.
I grew to respect those doctors and nurses that talked to me like a real person, and especially those that were honest enough with me enough to tell me
Portrait of a leader in immunotherapeutics
William Grossman Biothera; Eagan, MN USA they didn't always know what was going on with me, or how things were going to end up. I'll never forget going in for my umpteenth spinal tap and intrathecal antibiotics when I asked the anesthesiologist who was doing the tap if "…any of this is working for me." He stopped just short of inserting the needle in my back (…also no locals anesthetics back then). He let me come out of my fetal position, rolled his chair around the table to come face-toface, and said quietly to me "Billy, I really don't know because we're not sure what is wrong with you. We're just trying to do our best to make you better." It was one of the first time I remember that someone was honest with me during that summer and fall of 1977.
A few months after the initial onset of my symptoms things seemed to slowly resolve on their own. Once I was almost fully recovered, I was referred to the Mayo Clinic to see if they could diagnose what I had that led to my hospitalization. The diagnoses ranged from the original bacterial meningitis, to a possible tickborne disease (Lyme's disease and Ehrlichiosis were not well described yet at the time). I'm not sure I'll ever know what I had, but that experience solidified two major things in my mind. First, the medical profession was full of unknowns just waiting to be discovered, and second, that there was a need to develop new ways of diagnosing and compassionately treating patients.
In college I focused my energy on studying for my chemistry and biology majors, and spending all my spare time devoted to my independent research studies. When it came time to apply to medical schools, I made one decisionthat I would put all my faith into becoming the 'physician scientist' that I wanted to be since 2nd grade, and applied only to Medical Scientist Training Programs. I entered the program at Washington University School of Medicine (WUSM) where I knew they had one of the best Immunology Graduate Programs (and Medicine) in the country. Immunology was a field of science that I was turned onto at an early age by reading all of the Scientific American articles on HIV and Cancer. I knew that I wanted to bridge the sciences of virology, immunology, and cancer biology-so I specifically sought out labs at WUSM where I could learn all three areas.
The only laboratory that appeared to offer this challenge of bridging these three areas of science was that of Dr Lee Ratner, a physician scientist himself, who trained in the laboratory of Dr Robert Gallo. He was the lead author on the Science article that demonstrated through genetic sequencing that the suspected virus that caused AIDS was actually a retrovirus. His lab also drew my attention because he was also focusing on the genetic and immunological mechanisms of oncogenic transformation by the first human retrovirus, HTLV-I. It was during my studies on HTLV-I that I started honing my scientific interest in tumor development, as well as the interface between oncology and the immune system. During my early medical school rotations, I quickly learned that there was still relatively little known about what genetic defects resulted in human immunological disorders, many of which predisposed individuals to the development of cancer. At the time, there were only about a dozen genetically defined defects in the immune system (in contrast, there are now well over 150 genetically defined primary immunological disorders). I realized that if I really wanted understand the how defects in the immune system lead to different clinical manifestations, I needed to be in a position to learn from them firsthand. In my mind, the only way to witness this was to see them as they evolved from birth to childhood, so I decided to do my fellowship in Pediatric Hematology/Oncology/BMT at St. Louis Children's Hospital (SLCH), a program that was in part responsible for taking care of the sickest kids with immune defects. I also knew that the SLCH Pediatric Department had some of the most brilliant clinical immunologists, including Drs Chatila Talal and Jonathan Gitlin, as well as frequent visits from one of the grandfathers of clinical immunology, Dr Fred Rosen.
During my fellowship I found my calling in clinical immunology and translational oncology/bone marrow transplantation. I reveled in trying to understand the defects of the immune system that led to different clinical disorders, especially primary immunodeficiencies, severe immune dysregulation syndromes, and also the development of cancer. It was also during this time that the human genome was being sequenced, including a major center at WUSM… finally, the ability of finding gene defects for clinical disorders was becoming (slightly) easier. Since 2011, dr Grossman has been working for the biotechnology company Biothera in eagan (mn, uSa) as Senior Vice President, research & development. Biothera is developing a natural gluco-polysaccharide that engages and directs natural innate immune system responses. this carbohydrate technology may be used to enhance current cancer drugs. dr Grossman heads all preclinical and clinical immunology, oncology and biomarker research programs, supports oncology trials, and leads external scientific collaborations.
Besides his career in industry, dr Grossman still holds the position of adjunct Professor at the medical college of Wisconsin, and he serves as clinical and medical consultant for the children's Hospital of Wisconsin and the Wisconsin State Hygiene Laboratory, respectively. He has published about 40 papers in peer-reviewed scientific journals, and has also contributed to several books and manuals related on hematology and oncology. during the course of his career, dr Grossman received numerous honours and awards; for instance, he was repeatedly listed in the database Best doctors in america-State and nation.
During my time at SLCH, there were two patients who grabbed my attention in particular, both of which ultimately led me down my academic scientific pathway. One patient was a child who developed multiple, severe, life-threatening autoimmune disorders from birth, ultimately requiring a BMT. The second child was not quite as severe from an autoimmune perspective, but also had problems with clearing essentially all viruses he encountered. The first child went on to become one of the first patients described to have a deficiency of the FOXP3 gene by Dr Talal, which has since become known as the master regulatory gene required for T regulatory cell development. The second child was found by my colleague Dr James Verbsky at SLCH to have a deficiency in in a subunit of the IL-2 receptor, CD25, which was subsequently found to be a marker and essential receptor for human T regulatory cell function and development. At the time, it was somewhat taboo to work on this 'new field' of T regulatory cells, which were essentially a rediscovery of an older known subset of immune cells called "suppressor cells." But observing these human defects and their evolution firsthand led me, and my colleague Dr Verbsky, into trying to understand more about how this very small subset of T cells functioned and ultimately controlled both good (eg, viral responses) and bad (autoimmune) immune responses in our laboratories.
Dr Verbsky and I both ended up moving to the same academic institution, the Children's Hospital of Wisconsin (CHW)/ Medical College of Wisconsin (MCW) a year a part. When I first interviewed for the position in the BMT program at CHW, I had three major requests of then Pediatric Chair Dr Robert Kliegman: (1) I needed to take over the oncology/immunology clinical flow cytometry diagnostic laboratory, (2) I needed my translational research laboratory to be on the same floor as the diagnostic laboratory, and (3) I needed support to start the first multidisciplinary clinical immunology clinic and transplant program. I knew it was going to be critical to be the Medical Director of the diagnostic laboratory, in order to develop the tests that we needed to diagnose the patients we were seeing in our clinics, and to help describe and discover new disorders that we had been seeing all the time in our training-but didn't have the tools at our fingertips to figure them out.
It was seeing dozens and dozens of previously undiagnosed children during my first few years at SLCH that continued to drive my desire to develop better diagnostic tests. I wanted to optimize what it meant to be a 'translational researcher'-taking what you see in the clinic, to the research bench top to figure out the science of the disorders, and then back to the clinic to optimize your care for the patient. It was then that I saw the next child that drove my career for the next few years. It was a 15 month old male patient that I was called to consult on in the ICU with what appeared to be disseminated varicella. He had just received his chickenpox vaccine a couple of weeks prior, and although mild cases of chickenpox can occur after the vaccine, this was severe. He was pretty 'old' for a severe combined immune deficiency (SCID) patient to presenting, but given the severity of his disease, we immediately sent off his blood to our diagnostic laboratory for evaluations. It came back with what we all had hoped against-he had SCID, and now a virus infection was likely to take his life. But it was worse yet. It was then revealed that not only did he receive his chickenpox vaccine, but he had also received three other live-attenuated vaccines (Measles, Mumps and Rubella). Sadly to say, he developed severe disseminated cases of all 4 vaccinations and suffered miserably in the ICU until he ultimately succumbed approximately 2 months later. He certainly wasn't the first SCID patient of mine to die from an infection before they could receive a life-saving BMT, but I was determined he would be one of my last as there were readily available simple diagnostic tests to find patients like him.
Although there had been major advances in understanding the genetics of SCID through the human genome project at the time, one problem remained: How do you identify those newborns before they develop life-threatening infections so they can be cured with a BMT? A simple CBC with differential is able to diagnose most newborns with SCID, but unfortunately even this old hematology test was too expensive to deploy into mass screening efforts. We needed to develop something that was sensitive and specific, yet cheap enough to incorporate into newborn screening programs throughout the country.
It was around that time that Dr John 'Jack' Routes came to CHW/MCW as Division Chief of the Allergy/Immunology program. He was an adult clinical immunologist from National Jewish Hospital, but quickly identified this problem of identifying newborns with SCID as a real issue that had to be addressed. We had what we believed was a reliable realtime PCR screening methodology, originally applied in the HIV field to quantify naiive and memory T cells, which could be applied to newborn screening (NBS) cards. Now came the hard part-raising the money to see if we were right. Dr Routes went on to get $250,000 dollar commitments from both CHW as well as the Jeffrey Modell Foundation for primary immunodeficiencies. Next, Dr Routes and myself went to the Wisconsin Newborn Screening Laboratory annual meeting and presented our case. We immediately gained the attention and support of Drs. Ronald Laessig (outgoing director) and Charles Brokopp (outgoing director), who developed a scientific investigational group under the direction of Dr Mei Baker. Once we had further qualified the assay on real SCID patient samples I was seeing in the hospital, Dr Baker's group then validated the assay and determined that it ready to start a full-scale pilot study and incorporate it in the Wisconsin NBS program as a screening assay for SCID. Simultaneously, my diagnostic laboratory also developed a cheap confirmatory flow cytometry diagnostic test, which was going to be essential to confirm the diagnosis of SCID on any sample that may be identified by the NBS assay.
After 3 years, and successfully screening more than 200,000 Wisconsin newborns, we proved that we had developed a cheap and sensitive screening assay that could be successfully incorporated into any NBS program across the world. More importantly, we identified dozens of newborns with immunodeficiencies, including those with SCID, who went onto receive life-saving transplant before they succumbed to life-threatening infections. Our SCID screening program became the first in the country to start screening for SCID as part of the NBS program. Since then, several additional states have started screening for SCID through similar methodologies, and it is currently estimated that over 2 million newborns have been screened for this deadly, but curable disorder.
After spending a few additional years in academics, I decided to try and apply what I had been learning in my other scientific research programs in immunology/oncology at a larger scale. I wanted to start evaluating how to manipulate the immune system into attacking cancer cells. However, it was clear getting the funding and resources to start this endeavor was not going to come as easy as it did for our SCID screening program. So I turned to where there were more resources-pharmaceutical industry. I took a Medical Director position within Merck Oncology, where I had an opportunity to start on a tumor vaccine program. Unfortunately at the time, there had been no real successes in cancer immunomodulation or tumor vaccines, so although there were clearly more resources than in academics some of the same hurdles existed.
Fortunately, the pharmaceutical industry has had two major successes in this area in the form of Provenge  (prostrate vaccine) and Yervoy  (immunomodulatory agent/CTLA-4 blocking antibody for melanoma). With these two agents, the pharmaceutical industry has once again reason to believe we can successfully manipulate the immune system in the fight against cancer after decades of failures. However, the percentage of patients that develop long-term survival to these interventions has not quite met the expectations of the medical community.
Unfortunately, the complexity of the immune system has made it crystal clear from these two agents that not everyone can be expected to respond to treatments in the same manner, and that the 'magic bullet' to cancer treatment still eludes us and is unlikely to exist. So just like chemotherapeutic agents, most immunomodulatory agents should not be expected to fall into a 'one fit all' approach. Developing single agents and measuring 'success' in terms of small percentage changes in progression-free survival will also need to change.
After spending my whole academic and scientific career trying to manipulate the adaptive immune system for cancer therapy, I have recently taken a position at a small biotechnology company call Biothera which I believe is taking a truly novel approach at cancer: trying to 'trick' the innate immune cells, cells not normally thought to be involved fighting cancer, into attacking cancer cells much like they would an infectious organism. Cancer immunotherapy researchers-including myself-have historically ignored these cells but it has become clear that we need to approach cancer from multiple angles. The complexity of the immune system has taught us that we can't just go after a small fraction of immune cells and ignore the rest of them. If ultimately we're right, this immunomodulatory approach could be combined with almost any anti-tumor targeted monoclonal antibody. However, like any other agent, we will undoubtedly find the need to combine this approach with others. That's why we continue to spend most of our research into understanding our mechanism(s) of action to the best of our ability, and to push forward with our goal of finding a predictive biomarker of response. If we're fortunate in this regard, we hope that we'll be able to take that knowledge one step further into understanding and developing a way to treat those that wouldn't be expected to benefit from our approach I continue to be humbled every day around the complexities of the immune system and understanding how to find better therapies and approaches to treating cancer patients. However, I am optimistic that we will embrace true personalized medicine approaches in the future, and shift the paradigm of how we develop oncology drugs for the benefit and compassionate care of our patients.
